Atlas Trials

Avidity Biosciences, Inc.

11 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Avidity Biosciences, Inc.

RecordFirmDate
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping (NCT07587242)Avidity Biosciences, Inc.2026-08-01
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 (NCT07008469)Avidity Biosciences, Inc.2025-06-26
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD (NCT07038200)Avidity Biosciences, Inc.2025-06-10
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (NCT06547216)Avidity Biosciences, Inc.2024-07-25
Global Study of Del-desiran for the Treatment of DM1 (NCT06411288)Avidity Biosciences, Inc.2024-05-30
Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping (NCT06244082)Avidity Biosciences, Inc.2024-01-22
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (NCT05747924)Avidity Biosciences, Inc.2023-04-04
Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping (NCT05670730)Avidity Biosciences, Inc.2022-11-09
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients (NCT05479981)Avidity Biosciences, Inc.2022-08-04
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients (NCT05027269)Avidity Biosciences, Inc.2021-10-28

Track Avidity Biosciences, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.